Inclusion Criteria:~* Has a diagnosis by the study investigator of a clinical syndrome of cognitive impairment
consistent with prodromal AD per International Working Group (IWG) diagnostic criteria or mild cognitive
impairment (MCI) due to AD per National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic
criteria.~* Scores 17-28 on Montreal Cognitive Assessment (MoCA) at screening.~* Scores <27 on free recall
cutoff score from the Free and Cued Selective Reminding Test (FCSRT) (Picture version) at screening.~* Scores
â‰¤4 on Modified Hachinski Ischemia Scale (MHIS).~* Scores >0 on the Functional Activities Questionnaire (FAQ).~*
Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result at screening
consistent with the presence of amyloid pathology.~
